Compare iShares MSCI Australia ETF (EWA) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.55 (market cap $1.19B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 8.6× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWA | GMED | |
|---|---|---|
Market Cap | $1.19B | $10.25B |
Volume | 5,792,656 | 1,059,528 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $96.82 |
52-Week Low | $24.95 | $58.33 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77, up 0.35% today, but technical indicators signal a bearish trend with moving averages and key oscillators like the 6-day RSI at 75.94 suggesting overbought conditions. The ETF tracks Australian equities, heavily weighted toward commodities and financials, with recent news highlighting institutional selling by Squarepoint Ops LLC amid broader market concerns over inflation and oil price volatility.
The outlook for EWA hinges on commodity demand and global economic trends, offering exposure to Australia's resource-driven economy but facing risks from inflation and geopolitical tensions. Analyst sentiment is mixed, with Seeking Alpha rating it a Buy targeting over 20% upside, while technical weakness and institutional selling pose near-term headwinds.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
